利拉鲁肽对2型糖尿病合并非酒精性脂肪性肝病患者心血管的保护作用

发布时间：2018-03-31 03:03

本文选题：型糖尿病　切入点：非酒精性脂肪肝　出处：《中国老年学杂志》2017年23期

【摘要】：目的探讨胰高血糖素样肽(GLP)-1受体激动剂利拉鲁肽对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者心血管的保护作用。方法选择初诊T2DM合并NAFLD患者66例,随机分为二甲双胍联合吡格列酮治疗组(M+P组)和利拉鲁肽治疗组(Lira组),两组均治疗12 w,比较两组心血管相关风险因素的变化。结果两组治疗前体质指数(BMI)、腰臀比(WHR)、收缩压(SBP)、舒张压(DBP)、空腹血糖(FPG)、餐后2 h血糖(2 hPPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、胰岛素抵抗(HOMA-IR)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDLC)、脂联素(ADP)、高敏C-反应蛋白(hs-CRP)水平比较差异均无统计学意义(P0.05),经12 w治疗后Lira组均显著优于M+P组(P0.05)。两组在治疗期间均无明显不良反应。结论利拉鲁肽治疗可改善T2DM合并NAFLD患者心血管相关危险因素,对心血管有一定的保护作用。
[Abstract]:Objective to investigate the protective effect of lilalopeptide on cardiovascular function in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAF LDD). Methods 66 patients with newly diagnosed T2DM combined with NAFLD were selected. They were randomly divided into metformin combined with pioglitazone treatment group (M P group) and Rilalutide treatment group (Lira group). Both groups were treated for 12 weeks. The cardiovascular risk factors were compared between the two groups. Results the body mass index (BMI) and waist-gluteus index (WHR) before treatment were compared between the two groups. Compared with WHRX, SBP, DBP, FPGN, 2 h postprandial glucose, HbA1cU, FINSN, HOMA-IRN, TGG, LDLC, adiponectin, hs-CRP, hs-CRP) water. After 12 weeks of treatment, Lira group was significantly better than M P group (P 0.05). There was no significant adverse reaction in both groups during the treatment. Conclusion Lilalutide treatment can improve cardiovascular risk factors in T2DM patients with NAFLD. It has certain protective effect on cardiovascular system.
【作者单位】：吉林省人民医院内分泌二科;
【基金】：吉林省卫生计划生育委员会资助项目(No.20142007)
【分类号】：R575.5;R587.1

【相似文献】